Saturday 31 May, 2025 09:54 AM
Site map | Locate Us | Login
   Apollo Hospitals Q4 PAT jumps 13% YoY to Rs 390 cr    SML Isuzu gains after Q4 PAT rises 1% YoY to Rs 53 cr    Alembic Pharma receives USFDA final approval for Bosutinib tablets    Dynamic Cables gains after board declares 1:1 bonus issue    Samhi Hotels Q4 PAT jumps 306% YoY to Rs 46 cr    Welspun Living Ltd leads losers in 'A' group    Sobha gains after Q4 PAT soars 481% YoY to Rs 41 cr    Kiri Industries Ltd leads losers in 'B' group    SJVN slumps on reporting dismal Q4 PAT    Crisil Ratings assigns 'A1+' rating to commercial paper of Muthoot Microfin    Volumes soar at Gujarat Pipavav Port Ltd counter    ICRA reaffirms ratings of Ethos at 'A+' with 'stable' outlook    EFC (I) surges after PAT rises over 71% YoY in Q4; EBITDA margin at 51.8%    Metal shares fall    United Spirits Ltd down for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr
29-May-25   15:50 Hrs IST

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st March 2025.

EBITDA stood at Rs 614.4 crore, registering the growth of 13.93% compared with Rs 539.3 crore posted in corresponding quarter last year. EBITDA margin reduced to 47.7% in Q4 FY25 as against 48.6% in Q4 FY24.

During the quarter, the company recorded an impairment charge of Rs 50 crore in the crop health science business related to property, plant and machinery and a chargeback adjustment of approximately Rs 25 crore in its US subsidiary.

On full year basis, the company's consolidated net profit jumped 35.8% to Rs 1,885.40 crore on 10.8% increase in revenue from operations to Rs 4,429.50 crore in FY25 over FY24.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts Hit Count : 41228876
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited